ADIL - EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder | Benzinga
Wednesday, Adial Pharmaceuticals Inc. (NASDAQ:ADIL) announced that the first patient had been dosed in a pharmacokinetics study of AD04 for Alcohol Use Disorder in heavy drinking patients.
The study is expected to take six months to complete and is intended to produce data that will help the company optimize the study design elements needed for the upcoming Phase 3 clinical trial of AD04.
Completion of this study will also satisfy a requirement of the FDA guidance for the upcoming Phase 3 clinical trial of AD04.